January 23, 2012
09:16 EDT YMI
theflyonthewall.com: YM Biosciences reported compelling data, says Roth Capital
Roth Capital believes that YM reported differentiated efficacy data, especially with regard to positive anemia responses, at ASH. The firm thinks that the company will land a major partnership n 1H12 and it reiterates a $6 target and Buy rating on the stock.
YMI should start a new move higher....rare
All my posts are my opinions. Investors should do there own DD!!
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM